Claims for Patent: 7,223,387

Summary for Patent: 7,223,387

Title:	Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Abstract:	A topical composition comprising an antiinflammatory glucocorticoid and a nucleoside analogue antiviral agent in a pharmaceutical carrier characterized in that the carrier comprises about 15 to about 25 weight % propylene glycol and about 10 to about 25 weight percent isopropyl C.sub.12 C.sub.22 alkanoic ester. The compositions have utility in the treatment or prophylaxis of herpesvirus infections and exhibit superior antiviral and therapeutic efficacy and an improved shelf life.
Inventor(s):	Lekare; Gunilla (Borlange, SE)
Assignee:	Medivir AB (Huddinge, SE)
Application Number:	10/334,487
Patent Claims:	1. A topical composition in the form of an oil in water emulsion comprising the lipophilic glucocorticoid hydrocortisone and a lipophobic acyclic nucleoside antiviral wherein the oil phase contains at least one member of the group consisting of mineral oil, alkanoic acids, fatty alcohols, straight chain mono alkyl esters, branched chain mono alkyl esters, straight chain dibasic alkyl esters and branched chain dibasic alkyl esters and contains said hydrocortisone; and said water phase contains 0.05 5% weight percent emulsifier and said acyclic nucleoside antiviral selected from the group consisting of acyclovir, penciclovir and 9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine, the composition further comprising propylene glycol and isopropyl C.sub.12 C.sub.22 alkanoic acid ester selected from the group consisting of dodecanate, myristate, palmitate, stearate, eicosanate or behenoate esters, and mixtures thereof, wherein said hydrocortisone is 0.5 to 2 weight percent, said antiviral is 1 to 7 weight percent, said propylene glycol is 18 to 22 weight percent and said isopropyl C.sub.12 C.sub.22 alkanoic acid ester is 12 to 18 weight percent. 2. The composition according to claim 1 wherein the isopropyl alkanoic ester is isopropyl myristate. 3. The composition according to claim 1, wherein the nucleoside antiviral is acyclovir. 4. The composition according to claim 1, wherein the antiviral is acyclovir or penciclovir. 5. The composition according to claim 1, wherein acyclovir comprises 4 7 weight percent and hydrocortisone comprises 0.5 2 weight percent of the composition. 6. The composition according to claim 1, wherein penciclovir comprises 1 7 weight percent and hydrocortisone comprises 0.5 2 weight percent of the composition. 7. A method for the treatment of herpesvirus infections comprising the topical administration of a composition as defined in claim 1 to a subject in need thereof. 8. The composition according to claim 1, wherein the carrier comprises 20 weight percent propylene glycol. 9. The composition according to claim 1, wherein the carrier comprises 15 weight percent isopropyl alkanoic acid ester. 10. The composition according to claim 1, wherein the nucleoside antiviral comprises 4 7 weight percent of the composition. 11. The composition according to claim 1, which comprises 15 weight percent isopropyl myristate. 12. The composition according to claim 1, wherein said mineral oil is vaseline or liquid paraffin. 13. The composition according to claim 1, wherein said alkanoic acid is stearic acid. 14. The composition according to claim 1, wherein said fatty alcohol is cetostearyl alcohol. 15. The composition according to claim 1, wherein said emulsifier is poloxamer 188 or sodium lauryl sulphate. 16. The composition according to claim 1, wherein said oil phase is cetostearyl alcohol, vaseline and liquid paraffin. 17. The composition according to claim 1, wherein said emulsifier is poloxamer 188 and sodium lauryl sulphate. 18. The composition according to claim 1, wherein said antiviral is 5 weight percent acyclovir. 19. The composition according to claim 5, wherein said acyclovir is 5 weight percent and said hydrocortisone is 1 weight percent. 20. A method for the treatment of humans having or being at risk of developing herpesvirus infections comprising the topical administration of a composition as defined in claim 1.